News

Intradigm will use series B funds to advance its RNA interference therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its proprietary delivery

With this clearance, the device may now be utilized during procedures of the skin, subcutaneous tissues and nasal passages, for applications in podiatry, dermatology, plastic surgery, and otolaryngology.

The first five patients in this 60-patient trial have already been enrolled. During the study’s initial cranial surgical procedures, the patients’ dura mater was successfully repaired by surgeons

As in previous trials, this study has reportedly demonstrated a clear dose response relationship with four out of the six treatment groups achieving statistically significant clearance of AK

According to the company, the trainer, code named ‘SEATD’ (Stock Emergency Airway Training Device), provides dynamic anatomical replication, enabling superior, realistic teaching and training scenarios for all surgical

The Phase II multi-center, double-blind, placebo-controlled trial will be conducted in the US and will evaluate the analgesic efficacy and safety of intravenous CR845 during the post-operative period

Under the terms of the agreement, Champions will use its Biomerk Tumorgraft preclinical platform to evaluate a combination therapy indication for Salirasib, a Ras antagonist. This agreement modifies

The proceeds from the financing will be used to provide the financial flexibility to advance partnering and M&A discussions for Urigen’s URG101 program for painful bladder syndrome and

Under the terms of the agreement, AuricX gained rights from SRI to oral formulations of the antibiotic vancomycin. SRI received upfront payments and will be eligible for success-based